Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
Publication Date: November 29, 2018
Key Points
Key Points
Women with node-positive breast cancer should receive extended therapy including an aromatase inhibitor (AI) for up to a total of 10 years of adjuvant endocrine treatment.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors.
The benefits in absolute risk of reduction were modest, and, for lower risk node-negative or limited node positive cancers, an individualized approach to treatment duration based on considerations of risk reduction and tolerability was appropriate.
A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers.
Treatment
Treatment
...commendations on Extended Therapy...
...women with node-negative breast cancer are po...
...de-positive breast cancer should be offered exte...
...n receiving extended adjuvant endocrine therap...
...evention of secondary or contralateral breast canc...
...rapy carries ongoing risks and side...
Recommendations on Ovarian Suppression
...Panel recommends that higher risk pati...
Women with Stage II or Stage III breast...
...age I or II breast cancers at higher risk of r...
...tage I breast cancers not warranting chemot...
...omen with node-negative cancers 1 centim...
...rian suppression may be administered with eith...
.... Recommended Pharmaceuticals for...
...tic Factors for Recurrence After 5 Years of Adj...